Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole

M A Pfaller; D J Diekema; S A Messer; L Boyken; H Huynh; R J Hollis

doi:10.1128/JCM.40.5.1694-1697.2002

Back

Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole

Journal article

Open access

Peer reviewed

Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole

M A Pfaller, D J Diekema, S A Messer, L Boyken, H Huynh and R J Hollis

Journal of clinical microbiology, Vol.40(5), pp.1694-1697

05/2002

DOI: 10.1128/JCM.40.5.1694-1697.2002

PMCID: PMC130954

PMID: 11980944

Files and links (1)

url

https://doi.org/10.1128/JCM.40.5.1694-1697.2002View

Published (Version of record) Open Access

Abstract

A commercially prepared frozen broth microdilution panel (Trek Diagnostic Systems, Westlake, Ohio) was compared with a reference microdilution panel for antifungal susceptibility testing of two quality control (QC) strains and 99 clinical isolates of Candida spp. The antifungal agents tested included amphotericin B, flucytosine, fluconazole, itraconazole, posaconazole, ravuconazole, and voriconazole. Microdilution testing was performed according to NCCLS recommendations. MIC endpoints were read visually after 48 h of incubation and were assessed independently for each microdilution panel. The MICs for the QC strains were within published limits for both the reference and Trek microdilution panels. Discrepancies among MIC endpoints of no more than 2 dilutions were used to calculate the percent agreement. Acceptable levels of agreement between the Trek and reference panels were observed for all antifungal agents tested against the 99 clinical isolates. The overall agreement for each antifungal agent ranged from 96% for ravuconazole to 100% for amphotericin B. The Trek microdilution panel appears to be a viable alternative to frozen microdilution panels prepared in-house.

Antifungal Agents - pharmacology

Triazoles - pharmacology

Candida - classification

Humans

Voriconazole

Thiazoles - pharmacology

Candida - drug effects

Pyrimidines - pharmacology

Candida - isolation & purification

Microbial Sensitivity Tests - methods

Freezing

Details

Title: Subtitle: Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole
Creators: M A Pfaller - Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242, USA. michael-pfaller@uiowa.edu
D J Diekema
S A Messer
L Boyken
H Huynh
R J Hollis
Resource Type: Journal article
Publication Details: Journal of clinical microbiology, Vol.40(5), pp.1694-1697
DOI: 10.1128/JCM.40.5.1694-1697.2002
PMID: 11980944
PMCID: PMC130954
NLM abbreviation: J Clin Microbiol
ISSN: 0095-1137
eISSN: 1098-660X
Publisher: United States
Language: English
Date published: 05/2002
Academic Unit: Infectious Diseases; Epidemiology; Pathology; Internal Medicine
Record Identifier: 9983986368902771

Metrics

19 Record Views

14 Times Cited - Web of Science